PRRT for Neuroendocrine Tumours in Germany

If your oncologist has mentioned PRRT for neuroendocrine tumours in Germany, you probably have a lot of questions. Does it work? Is it safe? And is it worth travelling for?

Neuroendocrine tumours (NETs) grow from hormone-making cells, most often in the gut or pancreas. Many grow slowly, so people can live with them for years. When a tumour starts to grow or has spread, doctors look at targeted options, and PRRT is one of the main ones.

This guide explains what PRRT is, who it suits, what a cycle involves, and what the trials really show. We’ll be honest about where the evidence is strong and where it’s thinner. At the end, we’ll cover how the Cancer Rounds team arranges cancer treatment in Germany for international patients.

What Is PRRT and How Does It Work?

PRRT is a targeted radiation treatment. A radioactive atom, usually lutetium-177, is attached to a molecule that locks onto somatostatin receptors on neuroendocrine tumour cells. After an infusion, the radiation reaches the tumour with a limited effect on nearby healthy cells.

Many neuroendocrine tumours carry a lot of these receptors, which is why doctors scan for them before offering PRRT. Treatments like this belong to a group called radioligand therapies. The same idea is behind Lu-177 PSMA therapy for prostate cancer, which aims at a different protein.

Who Is a Good Candidate for PRRT?

PRRT is mainly used for adults with advanced neuroendocrine tumours that can’t be removed by surgery and that show strong somatostatin receptor uptake on a special PET scan. PRRT is commonly used for adults with advanced, somatostatin-receptor-positive neuroendocrine tumours (NETs), particularly well-differentiated tumours that cannot be removed surgically or have progressed despite earlier treatment. Suitability depends on the tumour’s origin, grade, receptor uptake, kidney function, blood counts and previous treatments.

In Europe, the established indication for lutetium-177 oxodotreotide includes selected adults with unresectable or metastatic, progressive, well-differentiated, somatostatin-receptor-positive gastroenteropancreatic NETs. Evidence from NETTER-2 also supports considering PRRT earlier for selected patients with higher-grade, well-differentiated disease.

Your doctors first need proof that the tumour carries enough receptors. Treatment protocols use a Ga-68 DOTATATE or DOTATOC PET scan for this. If uptake is weak, PRRT may not be the right choice.

Doctors also check your kidneys and bone marrow, because these are the organs they follow most closely after PRRT. The ENETS consensus guidance sets out eligibility criteria and minimum standards for centres.

PRRT isn’t only for people who have run out of options. In the NETTER-2 trial, people with newly diagnosed grade 2 or 3 tumours had it first, and the authors concluded it should be seen as a standard first-line option for that group.

PRRT for Neuroendocrine Tumours in Germany: Where and Why

German centres have treated large groups of NET patients with PRRT for many years. A registry of 450 patients from several German nuclear medicine departments reported a median survival of 59 months from the start of treatment. Serious (grade 3 to 4) kidney problems affected 0.2% of patients, and serious blood problems affected 2%.

Keep in mind that this was a registry, not a randomised trial. Many of those patients also had older yttrium-90 or combined treatments.

One centre in Bad Berka, an ENETS Centre of Excellence, analysed 1,048 patients. It found PRRT effective, with survival depending on the radionuclide used, the tumour grade and where the tumour began. German scientific societies have also published a joint guideline on who should receive PRRT and how it should be delivered.

German centres involved in the COMPETE trial included hospitals in Berlin, Essen, Hamburg, Marburg and Munich. Notable institutions offering specialist cancer care in these cities include Charité – Universitätsmedizin Berlin, University Hospital Essen, University Medical Center Hamburg-Eppendorf (UKE), University Hospital Marburg and LMU University Hospital Munich. Patients should confirm whether each centre currently offers PRRT and has experience treating their specific type of neuroendocrine tumour. To compare treatment options, see our guide to cancer hospitals in Germany.

What Happens During a PRRT Cycle?

A standard course is four infusions about eight weeks apart. On treatment day, an amino acid solution runs alongside the lutetium infusion to protect your kidneys. Scans and blood tests afterwards show how your tumour and body are responding.

Here’s how it usually unfolds:

• Records review : Your German team studies your scans, pathology report (which gives the tumour grade) and blood tests.
• Receptor PET scan : This confirms the tumour has enough receptors to be targeted.
• Infusion day : In one published trial protocol, amino acids start an hour before the infusion and continue for at least six hours afterwards. The lutetium infusion itself ran for about 20 minutes.
• Between cycles : Your team tracks your blood counts and kidney function, and repeats scans to check the response.

Your German team will tell you how long to stay at the hospital after each infusion.

How Well Does PRRT Work? What the Trials Show

The evidence for progression-free survival (the time before the tumour grows again) is strong. The evidence for overall survival is less clear, and it’s worth knowing both.

In NETTER-1, people with midgut tumours that had grown on a standard drug received PRRT or a higher dose of that drug. At 20 months, an estimated 65.2% of the PRRT group had no progression, compared with 10.8%. The final analysis put median survival at 48.0 months with PRRT and 36.3 months without, but that gap was not statistically significant.

NETTER-2 tested PRRT as first treatment for higher-grade tumours. It extended median progression-free survival by about 14 months.

The COMPETE trial, published in The Lancet in 2026, compared another lutetium-based PRRT with the pill everolimus. Median progression-free survival was 23.9 months versus 14.1 months, and serious treatment-related side effects were less common with PRRT (18% versus 40%).

For pancreatic tumours, a French trial compared PRRT with sunitinib. PRRT shrank tumours more often (63% versus 30%) and delayed progression longer, but overall survival was numerically longer in the sunitinib group. These trials can’t tell you how your own tumour will respond, which is why a specialist review of your scans matters.

What Are the Risks and Side Effects of PRRT?

Most side effects are mild and short-lived, such as nausea, tiredness and lower blood counts. The main long-term concerns are the kidneys and bone marrow. Serious problems are uncommon, but doctors follow patients for years to catch them early.

The most common side effects are nausea, vomiting, low blood cell counts, fatigue and reduced appetite.

Bone marrow is the bigger long-term question. In NETTER-1, 2 of 112 treated patients (1.8%) developed myelodysplastic syndrome, a blood disorder. A larger study of 807 patients found it in 2.35%, along with acute leukaemia in 1.1%.

Kidney changes were less frequent with lutetium alone than with yttrium-90. In that same study, 13.4% of lutetium-only patients had some kidney toxicity, compared with 33.6% of those given yttrium-90. Tell your team early if you already have kidney disease or a low blood count.

Planning PRRT in Germany as an International Patient

Travelling for treatment is easier when the steps are clear. Here’s how we usually work with patients:

• Send your records. Share your scans, pathology and recent blood tests. Our team replies within 4 hours, and you can start with an online second opinion if you want to confirm the plan first.
• Confirm receptor status. If you haven’t had a receptor PET scan, your German team will arrange one or review the one you have.
• Sort out the visa. We help with paperwork, and our guide to the medical visa for Germany explains what to expect.
• Understand the cost. PRRT is priced per cycle, and an indicative range is about €25,000 to €60,000 per cycle. The final amount depends on the clinic, your scans and tests, and the monitoring you need. See our page on cancer treatment costs in Germany for the wider picture.

A dedicated case manager stays with you from your first enquiry to your return home. Support is available in 11+ languages, so you’re never explaining your diagnosis through a stranger. After your last cycle, follow-up scans can often be arranged with your doctor at home, and we help share the reports.

Key Takeaways and Next Steps

Three things are worth remembering. PRRT works best when the tumour is well differentiated and shows strong receptor uptake. The trials clearly show longer time before progression, though survival gains are less certain. And German centres bring years of hands-on experience with this treatment.

If you’re weighing PRRT, the next step is a proper review of your scans. Send your reports to Cancer Rounds, and our team will help you get a personalised treatment plan with a clear cost estimate. You can book a consultation, request a callback, or start a WhatsApp chat if you’d like to talk it through first.

You don’t need to have every answer today. You only need to start with one good conversation.

Frequently Asked Questions

How long does PRRT take?

A standard course is four cycles, each about eight weeks apart, as used in the NETTER-2 trial. That means roughly six months from your first cycle to your last. Each infusion day is short, but you’ll also need scans and blood tests between cycles.

How successful is PRRT?

In NETTER-1, an estimated 65.2% of treated patients had no progression at 20 months, compared with 10.8% on the comparison drug. Survival benefit was less certain, and the final analysis found no statistically significant gain in median overall survival. Results depend on tumour type, grade and receptor uptake.

Can PRRT be repeated if the tumour grows again?

Sometimes, but the evidence is still being built. A phase II trial is comparing repeat PRRT with everolimus in midgut tumours that progressed after an earlier course. Your specialist will weigh your response to the first course, your kidney and blood counts, and your other options.

How is PRRT different from everolimus, sunitinib or somatostatin analogue injections?

PRRT delivers radiation to receptor-carrying tumour cells through infusions, while everolimus and sunitinib are daily tablets that block growth signals. In the COMPETE trial, PRRT delayed progression longer than everolimus. Which option is best for you depends on your tumour, your earlier treatment and your other health conditions.

What tests do I need before PRRT?

You need a receptor PET scan to show that the tumour has enough somatostatin receptors. Your team will also check your blood counts and kidney function, since kidneys and bone marrow are the organs followed most closely. Bringing your pathology report helps confirm the tumour grade.

What affects the cost of PRRT in Germany?

The price depends on the clinic, the scans and lab tests you need before treatment, the monitoring during your stay, and the follow-up after each cycle. Centres don’t usually quote one flat rate. Our page on cancer treatment costs in Germany explains what a quote usually includes, and our team can request an estimate for your case.

Can international patients get PRRT in Germany?

Yes. German centres treat patients from abroad, and Cancer Rounds coordinates records review, centre selection, visa support, travel, language help and follow-up. Our guide to cancer treatment in Germany for international patients walks through the process.